DOI: https://doi.org/10.29363/nanoge.amamed.2022.006
Publication date: 22nd April 2022
The recent cutting-edge advances on nanomaterials is anticipated to overcome some of the therapeutic window and clinical applicability of many drug/peptide molecules and can also act as innovative theranostic platforms and tool for the clinic in the future [1-4].
In the last decade, research on cancer and cardiovascular diseases resulted in a new set of potential treatments with promising results in the clinics [5-9]. Amongst the different experimental treatments, active cancer immunotherapy and targeted to the injured heart hold great promise for the future treatment of these diseases. In this work, prominent nanosystems, such as biohybrid nanocomposites made of different nanoparticles (porous silicon and oncolytic virus) and cancer cell-based membrane materials are presented and discussed as potential platforms for the individualization of medical intervention and biomedical applications.
Examples on how these biohybrid nanomaterials can be prepared and scaled-up, as well as how they can be used to enhance the drug’s targetability, intracellular drug delivery for both cancer chemo- and immune-therapy applications as well as other applications, will be highlighted and discussed.
Overall, our results suggest that biohybrid nanomaterials are a versatile and advanced platform for treatment of different diseases with an interesting potential for present and future clinical impact given its easy tailorability to each patient.
[1] Zhang, [..], Santos*, M. Hai*, D. A. Weitz*, Proc. Natl. Acad. Sci. U.S.A. 2019, 116, 7744.
[2] Liu*, [...], Santos*, Adv. Mater. 2018, 30, 1703393.
[3] Ferreira*, [...], Santos*, Adv. Funct. Mater. 2018, 28, 1705134.
[4] Ferreira*, [...], Santos*, Small 2017, 13, 1701276.
[5] Fontana*, [...], Santos*, Adv. Mater. 2017, 29, 1603239.
[6] Fontana, [...], Cerullo*, Santos*, ACS Nano 2019, 13, 6477.
[7] Yong, [...], Santos*, Yang*, Nature Commun. 2019, 10, 3838.
[8] Fusciello, [...], Santos*, Cerullo*, Nature Commun. 2019, 10, 5747.
[9] Zhang, [..] Fang*, Santos*, Zhang*, Sci. Adv. 2022, 8, eabj8207.